[Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. / Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A Konsentierte Praxisempfehlungen für Kinder und Erwachsene.
Fortschr Neurol Psychiatr
; 90(5): 212-221, 2022 May.
Article
em De
| MEDLINE
| ID: mdl-35453158
ABSTRACT
Sialorrhea, uncontrolled, excessive drooling, accompanies different, mostly neurological disorders from childhood to adulthood. With incobotulinumtoxinA (Xeomin, IncoBoNT/A, Merz Pharmaceuticals GmbH), an approved medication for the treatment of sialorrhea has been available since 2019. Patient selection, possible therapy goals, treatment and the management of specific treatment situations build the focus of this interdisciplinary expert consensus recommendations with the intent to facilitate access to treatment and to contribute to qualified botulinum toxin therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sialorreia
/
Toxinas Botulínicas Tipo A
/
Doenças do Sistema Nervoso
Tipo de estudo:
Guideline
Limite:
Adolescent
/
Adult
/
Child
/
Humans
Idioma:
De
Ano de publicação:
2022
Tipo de documento:
Article